Cardiovascular Risk in Prostate Cancer—A Call to Action?

Atkins, Katelyn M.; Nikolova, Andriana P.

doi:10.1001/jamaoncol.2024.0860

JAMA Oncol

2024

DOI: 10.1001/jamaoncol.2024.0860

|View full text |Cite

Cardiovascular Risk in Prostate Cancer—A Call to Action?

Katelyn M. Atkins,

Andriana P. Nikolova

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer

Nierengarten

2024

Cancer

View full text Add to dashboard Cite

Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer

Nierengarten

2024

Cancer

View full text Add to dashboard Cite

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer

Reiss,

Vasalani,

Albert

et al. 2024

Medicina

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is a mainstay treatment for metastatic prostate cancer, improving progression-free survival. ADT suppresses the production of testosterone and reduces circulating levels of the hormone. Luteinizing hormone-releasing hormone (LH-RH) agonists are the most commonly used ADT modality. They can be given alone or in combination with androgen synthesis inhibitors or androgen receptor antagonists. An estimated 40% of prostate cancer patients will receive ADT as part of their therapy during their lifetime. However, ADT has numerous adverse effects, including an increased cardiovascular risk that impacts quality of life. Relugolix is an alternative form of ADT. It is the only oral gonadotropin-releasing hormone antagonist, circumventing injection site reactions, making it easier for patients to take, and thus increasing compliance. Testosterone suppression with relugolix is excellent and testosterone recovery after discontinuation is rapid. This paper reviews the ADT and anti-androgen treatment options for men with prostate cancer and the cardiovascular effects of these therapies. There is accumulating evidence that cardiovascular risk with relugolix is lower than with other ADT medications and also lower than with androgen synthesis inhibitors and androgen receptor antagonists. This paper provides insight into the use of different ADT regimens based on the cardiovascular status and circumstances. It explores strategies to mitigate negative cardiovascular consequences and highlights the need for further study.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cardiovascular Risk in Prostate Cancer—A Call to Action?

Cited by 2 publications

References 7 publications

Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer

Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer

Contact Info

Product

Resources

About